Switch theme
Sign up to access all valuation multiples
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
1977
452
LTM Revenue $196M
LTM EBITDA $22.6M
$747M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Axogen has a last 12-month revenue of $196M and a last 12-month EBITDA of $22.6M.
In the most recent fiscal year, Axogen achieved revenue of $187M and an EBITDA of $6.1M.
Axogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Axogen valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $159M | $187M | XXX | XXX | XXX |
| Gross Profit | $114M | $128M | XXX | XXX | XXX |
| Gross Margin | 72% | 68% | XXX | XXX | XXX |
| EBITDA | -$13.3M | $6.1M | XXX | XXX | XXX |
| EBITDA Margin | -8% | 3% | XXX | XXX | XXX |
| Net Profit | -$28.9M | -$21.7M | XXX | XXX | XXX |
| Net Margin | -18% | -12% | XXX | XXX | XXX |
| Net Debt | $30.4M | $15.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Axogen's stock price is $16.
Axogen has current market cap of $712M, and EV of $747M.
See Axogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $747M | $712M | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Axogen has market cap of $712M and EV of $747M.
Axogen's trades at 3.8x LTM EV/Revenue multiple, and 33.1x LTM EBITDA.
Analysts estimate Axogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Axogen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $747M | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 122.9x | XXX | XXX | XXX |
| P/E | -71.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 67942.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAxogen's NTM/LTM revenue growth is 16%
Axogen's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Axogen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Axogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Axogen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -146% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 19% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 78% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Axogen acquired XXX companies to date.
Last acquisition by Axogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Axogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Axogen founded? | Axogen was founded in 1977. |
| Where is Axogen headquartered? | Axogen is headquartered in United States of America. |
| How many employees does Axogen have? | As of today, Axogen has 452 employees. |
| Who is the CEO of Axogen? | Axogen's CEO is Mr. Michael J. Dale. |
| Is Axogen publicy listed? | Yes, Axogen is a public company listed on NAS. |
| What is the stock symbol of Axogen? | Axogen trades under AXGN ticker. |
| When did Axogen go public? | Axogen went public in 1986. |
| Who are competitors of Axogen? | Similar companies to Axogen include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Axogen? | Axogen's current market cap is $712M |
| What is the current revenue of Axogen? | Axogen's last 12-month revenue is $196M. |
| What is the current EBITDA of Axogen? | Axogen's last 12-month EBITDA is $22.6M. |
| What is the current EV/Revenue multiple of Axogen? | Current revenue multiple of Axogen is 3.8x. |
| What is the current EV/EBITDA multiple of Axogen? | Current EBITDA multiple of Axogen is 33.1x. |
| What is the current revenue growth of Axogen? | Axogen revenue growth between 2023 and 2024 was 18%. |
| Is Axogen profitable? | Yes, Axogen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
